Search

Your search keyword '"Akkoc, N."' showing total 360 results
Start Over Author "Akkoc, N."
360 results on '"Akkoc, N."'

1. Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]

Author

Ørnbjerg, L.M., Linde, L., Georgiadis, S., Rasmussen, S.H., Lindström, U., Askling, J., Michelsen, B., Giuseppe, D.D., Wallman, J.K., Pavelka, K., Závada, J., Nissen, M.J., Jones, G.T., Relas, H., Pirilä, L., Tomšič, M., Rotar, Z., Geirsson, A.J., Gudbjornsson, B., Kristianslund, E.K., Horst-Bruinsma, I.E. van der, Loft, A.G., Laas, K., Iannone, F., Corrado, A., Ciurea, A., Santos, M.J., Santos, H. Dos, Codreanu, C., Akkoc, N., Gunduz, O.S., Glintborg, B., Østergaard, M., Hetland, M.L., Ørnbjerg, L.M., Linde, L., Georgiadis, S., Rasmussen, S.H., Lindström, U., Askling, J., Michelsen, B., Giuseppe, D.D., Wallman, J.K., Pavelka, K., Závada, J., Nissen, M.J., Jones, G.T., Relas, H., Pirilä, L., Tomšič, M., Rotar, Z., Geirsson, A.J., Gudbjornsson, B., Kristianslund, E.K., Horst-Bruinsma, I.E. van der, Loft, A.G., Laas, K., Iannone, F., Corrado, A., Ciurea, A., Santos, M.J., Santos, H. Dos, Codreanu, C., Akkoc, N., Gunduz, O.S., Glintborg, B., Østergaard, M., and Hetland, M.L.

Abstract

Item does not contain fulltext

Published
2023

2. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS

Author

Molto, Anna, Gossec, Laure, Meghnathi, Bhowmik, Landewé, Robert B M, van der Heijde, Désirée, Atagunduz, Pamir, Elzorkany, Bassel Kamal, Akkoc, Nurullah, Kiltz, Uta, Gu, Jieruo, Wei, James Cheng Chung, Dougados, Maxime, Molto, A, Gossec, L, Meghnathi, B, RLANDEWE, Der heijde, D Van, Atagunduz, P, Zorkany, B El, Akkoc, N, Kiltz, U, Gu, J, Wei, J Cheng-chung, Pandya, M Dougados,s, Navarro, V, Gaydukova, I, Geher, P, Spoorenberg, A, Aydin, S, Pimentel, F, Kishimoto, M, Gallen, F Van, Collantes-estevez, E, Schiotis, R, Marzo-ortega, H, O’shea, B, Ramos-remus, C, and Magrey, And M

Published
2018
Full Text
View/download PDF

3. INCIDENCE OF ANTERIOR UVEITIS IN AXIAL SPONDYLOARTHRITIS DURING SECUKINUMAB TREATMENT: TWO YEARS REAL LIFE EXPERIENCE FROM TURKBIO REGISTRY

Author

Akleylek, C., Akar, S., Cinakli, H., Sagir, R. Piskin, COŞKUN, NEJDET, Karakas, A., Apaydin, H., Kardas, R. C., Isik, O. Ozdemir, Hakbilen, S., Okyar, B., Sosyal, O., Koca, S. S., PEHLİVAN, YAVUZ, DALKILIÇ, HÜSEYİN EDİZ, Can, G., Sari, I., BİRLİK, AHMET MERİH, Erten, S., ÖZTÜRK, AKİF MUHTAR, Yazici, A., Cefle, A., Yilmaz, S., ÇETİN, GÖZDE YILDIRIM, Akkoc, N., Yilmaz, N., and Onen, F.

Published
2022

4. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

Author

Christiansen, S.N., Ørnbjerg, L.M., Rasmussen, S.H., Loft, A.G., Askling, J., Iannone, F., Zavada, J., Michelsen, B., Nissen, M., Onen, F., Santos, M.J., Pombo-Suarez, M., Relas, H., Macfarlane, G.J., Tomsic, M., Codreanu, C., Gudbjornsson, B., Horst-Bruinsma, I.E. van der, Giuseppe, D. Di, Glintborg, B., Gremese, E., Pavelka, K., Kristianslund, E.K., Ciurea, A., Akkoc, N., Barcelos, A., Sánchez-Piedra, C., Peltomaa, R., Jones, G.T., Rotar, Z., Ionescu, R., Grondal, G., Sande, M.G. van de, Laas, K., Østergaard, M., Hetland, M.L., Christiansen, S.N., Ørnbjerg, L.M., Rasmussen, S.H., Loft, A.G., Askling, J., Iannone, F., Zavada, J., Michelsen, B., Nissen, M., Onen, F., Santos, M.J., Pombo-Suarez, M., Relas, H., Macfarlane, G.J., Tomsic, M., Codreanu, C., Gudbjornsson, B., Horst-Bruinsma, I.E. van der, Giuseppe, D. Di, Glintborg, B., Gremese, E., Pavelka, K., Kristianslund, E.K., Ciurea, A., Akkoc, N., Barcelos, A., Sánchez-Piedra, C., Peltomaa, R., Jones, G.T., Rotar, Z., Ionescu, R., Grondal, G., Sande, M.G. van de, Laas, K., Østergaard, M., and Hetland, M.L.

Abstract

Item does not contain fulltext, OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. METHODS: Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. RESULTS: In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. CONCLUSION: Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.

Published
2022

5. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

Author

Nissen, M., Delcoigne, B., Giuseppe, D. Di, Jacobsson, L., Hetland, M.L., Ciurea, A., Nekvindova, L., Iannone, F., Akkoc, N., Sokka-Isler, T., Fagerli, K.M., Santos, M.J., Codreanu, C., Pombo-Suarez, M., Rotar, Z., Gudbjornsson, B., Horst-Bruinsma, I.E. van der, Loft, A.G., Möller, B., Mann, H., Conti, F., Cetin, G. Yildirim, Relas, H., Michelsen, B., Ribeiro, P. Avila, Ionescu, R., Sanchez-Piedra, C., Tomsic, M., Á, J. Geirsson, Askling, J., Glintborg, B., Lindström, U., Nissen, M., Delcoigne, B., Giuseppe, D. Di, Jacobsson, L., Hetland, M.L., Ciurea, A., Nekvindova, L., Iannone, F., Akkoc, N., Sokka-Isler, T., Fagerli, K.M., Santos, M.J., Codreanu, C., Pombo-Suarez, M., Rotar, Z., Gudbjornsson, B., Horst-Bruinsma, I.E. van der, Loft, A.G., Möller, B., Mann, H., Conti, F., Cetin, G. Yildirim, Relas, H., Michelsen, B., Ribeiro, P. Avila, Ionescu, R., Sanchez-Piedra, C., Tomsic, M., Á, J. Geirsson, Askling, J., Glintborg, B., and Lindström, U.

Abstract

Item does not contain fulltext, OBJECTIVES: Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis. METHODS: Data was collected from 13 European registries. One-year outcomes included TNFi retention and hazard ratios (HR) for discontinuation with 95% CIs. Logistic regression was performed with adjusted odds ratios (OR) of achieving remission (Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP < 1.3 and/or BASDAI < 2) and stratified by treatment. Inter-registry heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Peripheral arthritis was defined as ≥1 swollen joint at baseline (=TNFi start). RESULTS: Amongst 24 171 axSpA patients, 32% received csDMARD co-therapy (range across countries: 13.5% to 71.2%). The co-therapy group had more baseline peripheral arthritis and higher CRP than the monotherapy group. One-year TNFi-retention rates (95% CI): 79% (78, 79%) for TNFi monotherapy vs 82% (81, 83%) with co-therapy (P < 0.001). Remission was obtained in 20% on monotherapy and 22% on co-therapy (P < 0.001); adjusted OR of 1.16 (1.07, 1.25). Remission rates at 12 months were similar in patients with/without peripheral arthritis. CONCLUSION: This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy.

Published
2022

6. AB0762 Incidence Of Anterior Uveitis In Axial Spondyloarthritis During Secukinumab Treatment: TWO YEARS REAL LIFE EXPERIENCE FROM TURKBIO REGISTRY

Author

Akleylek, C., primary, Akar, S., additional, Cinakli, H., additional, Piskin Sagir, R., additional, Coşkun, B. N., additional, Karakas, A., additional, Apaydin, H., additional, Kardaş, R. C., additional, Ozdemir Isik, O., additional, Hakbilen, S., additional, Okyar, B., additional, Sosyal, O., additional, Koca, S. S., additional, Pehlivan, Y., additional, Dalkiliç, E., additional, Can, G., additional, Sari, İ., additional, Birlik, M., additional, Onen, F., additional, Erten, S., additional, Ozturk, M. A., additional, Yazici, A., additional, Cefle, A., additional, Yilmaz, S., additional, Yildirim Cetin, G., additional, Akkoc, N., additional, and Yilmaz, N., additional

Published
2022
Full Text
View/download PDF

8. SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 27189 BIO-NAIVE AXIAL SPONDYLOARTHRITIS PATIENTS INITIATING TNFI - RESULTS FROM THE EUROSPA COLLABORATION

Author

Gudbjornsson, B., Hetland, M. L., Ostergaard, M., Geirsson, A. J., Van De Sande, M. G. H., Ornbjerg, L. Midtboll, Christiansen, S. N., Rasmussen, S. H., Rotar, Z., Ionescu, R., Sanchez-Piedra, C., Hokkanen, A. M., Jones, G. T., Askling, J., Loft, A. G., Lindstrom, U., Zavada, J., Iannone, F., Barcelos, A., Kristianslund, E., Ciurea, A., Akkoc, N., Gremese, E., Pavelka, K., Glintborg, B., Onen, F., Nissen, M. J., Michelsen, B., Santos, M. J., Macfarlane, G., Nordstrom, D., Pombo-Suarez, M., Codreanu, C., Tomsic, M., and Van der Horst-Bruinsma, I.

Published
2021

11. POS0027 SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 27189 BIO-NAÏVE AXIAL SPONDYLOARTHRITIS PATIENTS INITIATING TNFI – RESULTS FROM THE EUROSPA COLLABORATION

Author

Midtbøll Ørnbjerg, L., primary, Christiansen, S. N., additional, Rasmussen, S. H., additional, Loft, A. G., additional, Lindström, U., additional, Zavada, J., additional, Iannone, F., additional, Onen, F., additional, Nissen, M. J., additional, Michelsen, B., additional, Santos, M. J., additional, Macfarlane, G., additional, Nordström, D., additional, Pombo-Suarez, M., additional, Codreanu, C., additional, Tomsic, M., additional, Van der Horst-Bruinsma, I., additional, Gudbjornsson, B., additional, Askling, J., additional, Glintborg, B., additional, Pavelka, K., additional, Gremese, E., additional, Akkoc, N., additional, Ciurea, A., additional, Kristianslund, E., additional, Barcelos, A., additional, Jones, G. T., additional, Hokkanen, A. M., additional, Sánchez-Piedra, C., additional, Ionescu, R., additional, Rotar, Z., additional, Van de Sande, M. G. H., additional, Geirsson, A. J., additional, Østergaard, M., additional, and Hetland, M. L., additional

Published
2021
Full Text
View/download PDF

12. Genetic susceptibility and phenotype of rheumatoid arthritis in Danish and Turkish patients

Author

Lauridsen, K. B., Linauskas, A., Rasmussen, C., Can, G., Onen, F., Dreyer, L., Steffensen, R., Nielsen, K. R., Steen Krogh, N., Akar, S., and Akkoc, N.

Abstract

Background: Previous studies indicate that genetic susceptibility and phenotype of rheumatoid arthritis (RA) differ between the populations.Objectives: To compare the clinical, serologic expression and the presence of shared epitopes (SE) of incident RA in two different populations, one from Northern and the other from Southern Europe.Methods: Data on incident RA patients fulfilling EULAR/ACR 2010 classifications criteria for RA were collected at Rheumatology Departments in Denmark and Turkey in 2015-2016. Patients were assessed using the same standardized protocol in both populations. SE carrier status were assigned, according to the du Montcel classification based, into six allele groups: S1, S2, S3D, S3P and X, where S2 and S3P are RA risk-enhancing alleles and S1 and S3D are RA protective alleles of the shared epitope(1).Results: 109 incident RA patients from Denmark and 114 incident RA patients from Turkey were enrolled. Genetic data were available from 87Table 1. Characteristics of incident rheumatoid arthritis patients in Denmark and TurkeyView this table:Table 2. Shared epitope allele carrier frequencies.We found no associations between the risk-enhancing alleles and the presence of IgM rheumatoid factor or ACPA.Conclusion: The Turkish patients were younger and had lower disease activity than Danish at the time of diagnosis. Our study found an enhanced genetic susceptibility to RA in Danish compared to Turkish patients with a higher prevalence of risk-enhancing RA alleles and a lower prevalence of protective alleles.References: [1]Tezenas du Montcel S, Michou L, Petit-Teixeira E, Osorio J, Lemaire I, Lasbleiz S, et al. New classification of HLAtextendashDRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum 2005; 52: 1063textendash8.Disclosure of Interests: None declared

Published
2020
Full Text
View/download PDF

19. SAT0097 DO COMORBIDITIES IMPACT PERSISTENCE OF FIRST TUMOR NECROSIS FACTOR INHIBITOR TREATMENT IN RHEUMATOID ARTHRITIS? DATA FROM TURKBIO

Author

Yüce İnel, T., primary, Kocaer, S. B., additional, Erez, Y., additional, Gulle, S., additional, Karakas, A., additional, Köken Avşar, A., additional, Uslu, S., additional, Can, G., additional, Sari, İ., additional, Birlik, M., additional, Dalkiliç, E., additional, Pehlivan, Y., additional, Akar, S., additional, Goker, B., additional, Yildirim Cetin, G., additional, Haznedaroglu, S., additional, Yavuz, Ş., additional, Pirildar, T., additional, Direskeneli, H., additional, Akkoc, N., additional, and Onen, F., additional

Published
2020
Full Text
View/download PDF

20. THU0390 THE INFLUENCE OF OBESITY ON RETENTION AND TREATMENT RESPONSE OF SECUKINUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: REAL LIFE DATA FROM THE TURKBIO REGISTRY

Author

Karakas, A., primary, Gulle, S., additional, Yüce İnel, T., additional, Uslu, S., additional, Köken Avşar, A., additional, Kocaer, S. B., additional, Erez, Y., additional, Can, G., additional, Birlik, M., additional, Yazici, A., additional, Tufan, A., additional, Dalkiliç, E., additional, Koca, S. S., additional, Akkoc, N., additional, Akar, S., additional, Sari, İ., additional, and Onen, F., additional

Published
2020
Full Text
View/download PDF

21. THU0378 DO COMORBIDITIES DECREASE THE FIRST TNF-INHIBITOR RETENTION AND TREATMENT RESPONSE IN AXIAL SPONDYLOARTHRITIS PATIENTS? DATA FROM TURKBIO

Author

Erez, Y., primary, Karakas, A., additional, Kocaer, S. B., additional, Yüce İnel, T., additional, Gulle, S., additional, Köken Avşar, A., additional, Uslu, S., additional, Can, G., additional, Sari, İ., additional, Birlik, M., additional, Dalkiliç, E., additional, Pehlivan, Y., additional, Senel, S., additional, Akar, S., additional, Koca, S. S., additional, Tufan, A., additional, Yazici, A., additional, Yilmaz, S., additional, Inanc, N., additional, Solmaz, D., additional, Akkoc, N., additional, and Onen, F., additional

Published
2020
Full Text
View/download PDF

22. OP0109 CO-MEDICATION WITH A CONVENTIONAL SYNTHETIC DMARD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH IMPROVED RETENTION OF TNF INHIBITORS: RESULTS FROM THE EUROSPA COLLABORATION

Author

Nissen, M., primary, Delcoigne, B., additional, DI Giuseppe, D., additional, Jacobsson, L. T. H., additional, Fagerli, K., additional, Loft, A. G., additional, Ciurea, A., additional, Nordström, D., additional, Rotar, Z., additional, Iannone, F., additional, Santos, M. J., additional, Pombo-Suarez, M., additional, Gudbjornsson, B., additional, Mann, H., additional, Akkoc, N., additional, Codreanu, C., additional, Van der Horst-Bruinsma, I., additional, Michelsen, B., additional, Macfarlane, G., additional, Hetland, M. L., additional, Tomsic, M., additional, Moeller, B., additional, Ávila-Ribeiro, P., additional, Sánchez-Piedra, C., additional, Relas, H., additional, Geirsson, A. J., additional, Nekvindova, L., additional, Yildirim Cetin, G., additional, Ionescu, R., additional, Steen Krogh, N., additional, Askling, J., additional, Glintborg, B., additional, and Lindström, U., additional

Published
2020
Full Text
View/download PDF

23. SAT0423 LONG-TERM SURVIVAL OF THE FIRST BIOLOGIC TREATMENT IN PSORIATIC ARTHRITIS AND THE EFFECT OF THE SELECTED TREATMENT ON DRUG SURVIVAL; TURKBIO REGISTRY

Author

Kocaer, S. B., primary, Yüce İnel, T., additional, Erez, Y., additional, Köken Avşar, A., additional, Uslu, S., additional, Karakas, A., additional, Gulle, S., additional, Can, G., additional, Sari, İ., additional, Birlik, M., additional, Dalkiliç, E., additional, Pehlivan, Y., additional, Akar, S., additional, Cefle, A., additional, Öztürk, M. A., additional, Yolbaş, S., additional, Yilmaz, N., additional, Erten, S., additional, Akkoc, N., additional, and Onen, F., additional

Published
2020
Full Text
View/download PDF

24. The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology

Author

Migliore, A, Scire, C, Carmona, L, Beaumont, G, Bizzi, E, Branco, J, Carrara, G, Chevalier, X, Collaku, L, Aslanidis, S, Denisov, L, Di Matteo, L, Bianchi, G, Diracoglu, D, Frediani, B, Maheu, E, Martusevich, N, Bagnato, G, Scarpellini, M, Minisola, G, Akkoc, N, Ramonda, R, Barskova, T, Babic-Naglic, D, Muelas, J, Ionescu, R, Rashkov, R, Damjanov, N, Cerinic, M, Migliore A., Scire C. A., Carmona L., Beaumont G. H., Bizzi E., Branco J., Carrara G., Chevalier X., Collaku L., Aslanidis S., Denisov L., Di Matteo L., Bianchi G., Diracoglu D., Frediani B., Maheu E., Martusevich N., Bagnato G. F., Scarpellini M., Minisola G., Akkoc N., Ramonda R., Barskova T., Babic-Naglic D., Muelas J. V. M., Ionescu R., Rashkov R., Damjanov N., Cerinic M. M., Migliore, A, Scire, C, Carmona, L, Beaumont, G, Bizzi, E, Branco, J, Carrara, G, Chevalier, X, Collaku, L, Aslanidis, S, Denisov, L, Di Matteo, L, Bianchi, G, Diracoglu, D, Frediani, B, Maheu, E, Martusevich, N, Bagnato, G, Scarpellini, M, Minisola, G, Akkoc, N, Ramonda, R, Barskova, T, Babic-Naglic, D, Muelas, J, Ionescu, R, Rashkov, R, Damjanov, N, Cerinic, M, Migliore A., Scire C. A., Carmona L., Beaumont G. H., Bizzi E., Branco J., Carrara G., Chevalier X., Collaku L., Aslanidis S., Denisov L., Di Matteo L., Bianchi G., Diracoglu D., Frediani B., Maheu E., Martusevich N., Bagnato G. F., Scarpellini M., Minisola G., Akkoc N., Ramonda R., Barskova T., Babic-Naglic D., Muelas J. V. M., Ionescu R., Rashkov R., Damjanov N., and Cerinic M. M.

Abstract

The aim of this study was to establish consensus for potential early symptomatic knee osteoarthritis (ESKOA) clinical definition and referral criteria from primary care to rheumatologists, based on available data from literature and a qualitative approach, in order to perform studies on patients fulfilling such criteria and to validate the obtained ESKOA definition. A complex methodological approach was followed including: (1) three focus groups (FG), including expert clinicians, researchers and patients; (2) a systematic literature review (SLR); (3) two discussion groups followed by a Delphi survey. FG and SLR were performed in parallel to inform discussion groups in order to identify relevant constructs to be included in the modified Delphi survey. ESKOA is defined in the presence of: (a) two mandatory symptoms (knee pain in the absence of any recent trauma or injury and very short joint stiffness, lasting for less than 10 min, when starting movement) even in the absence of risk factors, or (b) knee pain, and 1 or 2 risk factors or (c) three or more risk factors in the presence of at least one mandatory symptom, with symptoms lasting less than 6 months. These criteria are applicable in the absence of active inflammatory arthritis, generalized pain, Kellgren-Lawrence grade >0, any recent knee trauma or injury, and age lower than 40 years. Knee pain in the absence of any recent trauma lasting for less than 6 months was considered as the referral criterion to the rheumatologist for the suspicion of ESKOA. This consensus process has identified provisional clinical definition of ESKOA and defined potential referral criterion to rheumatologist, in order to test ESKOA obtained definition in prospective validation studies.

Published
2017

26. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

Author

Rudwaleit, M, van der Heijde, D, Landewé, R, Listing, J, Akkoc, N, Brandt, J, Braun, J, Chou, C T, Collantes-Estevez, E, Dougados, M, Huang, F, Gu, J, Khan, M A, Kirazli, Y, Maksymowych, W P, Mielants, H, Sørensen, I J, Ozgocmen, S, Roussou, E, Valle-Oñate, R, Weber, U, Wei, J, and Sieper, J

Published
2009
Full Text
View/download PDF

28. The validity and reliability study of the University of California, Los

Author

Tas, YM, Hakim, GD, Keskinoglu, P, Kenar, G, Yarkan, H, Zengin, B, Can, G, Onen, F, Akkoc, N, Birlik, M, and Akarsu, M

Subjects
Scleroderma, gastrointestinal system, validity, reliability, UCLA
Abstract

Background/Aims: To translate the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire from English to Turkish and to validate it. Materials and Methods: UCLA SCTC GIT 2.0 was translated into Turkish using the translation-retranslation method. The available Turkish GIT 2.0 and the Short Form 36 (SF-36) were administered to 97 Turkish-speaking patients with systemic sclerosis (Ssc). Internal consistency reliability and structural validity were assessed by analyzing the correlations between the UCLA SCTC GIT 2.0 and the SF-36 scales. Internal consistency was determined by calculating Cronbach's alpha. For evaluation of reliability, the questionnaire scale was repeatedly applied to a subgroup of patients with a 2-week interval, and the intraclass correlation coefficient (ICC) was calculated. The Spearman's correlation coefficients between the GIT and the SF-36 scores were calculated. Results: A group of 97 patients with Ssc with a mean age of 55.37 +/- 11.35 years and a female predominance (87.6%) were included in the study. The Cronbach's alpha value for the UCLA SCTC GIT 2.0 scale was 0.894. ICC was 0.821 (p=0.000). The scale showed acceptable reliability, with the exception of the diarrhea subscale (alpha=0.356). There was a moderate correlation between the total GIT score and the Short Form 36 (SF-36) subscales. All of the items in the scale were included in the validity analysis owing to their reliability. Conclusion: The Turkish GIT 2.0 scale showed good internal consistency, high reliability, and an acceptable validity. C1 [Tas, Yasar Murat] Pamukkale Univ, Div Nephrol, Dept Internal Med, Sch Med, Denizli, Turkey. [Hakim, Gozde Dervis] Tepecik Training & Res Hosp, Div Gastroenterol, Dept Internal Med, Izmir, Turkey. [Keskinoglu, Pembe] Dokuz Eylul Univ, Dept Biostat, Sch Med, Izmir, Turkey. [Kenar, Gokce; Yarkan, Handan; Zengin, Berrin; Can, Gercek; Onen, Fatos; Birlik, Merih] Dokuz Eylul Univ, Div Rheumatol, Dept Internal Med, Sch Med, Izmir, Turkey. [Akarsu, Mesut] Dokuz Eylul Univ, Div Gastroenterol, Dept Internal Med, Sch Med, Izmir, Turkey.

Published
2019

40. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative

Author

Dick, A. D., Rosenbaum, J. T., Al-Dhibi, H. A., Belfort, R., Brezin, A. P., Chee, S. P., Davis, J. L., Ramanan, A. V., Sonoda, K. -H., Carreno, E., Nascimento, H., Salah, S., Salek, S., Siak, J., Steeples, L., Accorinti, M., Acharya, N., Adan, A., Agrawal, R., Akkoc, N., Al Ghamdi, S., Al Ghamdi, T., Al Saati, A., Alsabaani, N., Al-Shamarani, M., Bachta, A., Barisani-Asenbauer, T., Beare, N., Porto, F. B. O., Blanco, R., Yee, A. C. S., Chandran, V., Chiquet, C., Chng, H. H., Cimbalas, A., Cimino, L., Cordero-Coma, M., Cristobal, C., Cuevas, M., Eurico da Fonseca, J., de Boer, J., de la Torre, A., De Schryver, I., Derzko-Dzulynsky, L., Diaz-Valle, D., Merino, C. E. D., Facsko, A., Figueira, L., Fonollosa, A., Fortin, E., Gale, R., Galeazzi, M., Garcia, S., Garcia Ruiz de Morales, J. M., Gaspersic, N., Goldstein, D., Guedes, M., Guex-Crosier, Y., Gul, A., Hamam, R., Haroon, M., Hasegawa, K., Heiligenhaus, A., Hooper, C., Hwang, Y. -S., Hwang, D. -K., Juanola, X., Kaburaki, T., Kadayifcilar, S., Kempen, J., Kezuka, T., Kherani, A., Kirsimae, M., Kotaniemi, K., Kraut, A., Kubicka-Trzaska, A., Kuffova, L., Lightman, S., Lim, L., Lim, W. K., Mccluskey, P., Mcguire, M., Mirabelli, P., Miserocchi, E., Misiuk-Hojlo, M., Muccioli, C., Munoz, S., Murphy, C., Murray, P., Nagy, Z., Namba, K., Neri, P., Nguyen, Q., O'Gradaigh, D., Omair, M., Otsa, K., Ozyazgan, Y., Pablo, F., Paroli, M. P., Pleyer, U., Poor, G., Proenca, R., Rabinovitch, T., Read, R., Rebrov, M., Recillas-Gispert, C., Rothova, A., Schwartzman, S., Seve, P., Sharma, S., Sims, J., Sohar, N., Suhler, E., Szanto, S., Szepessy, Z., Tappeiner, C., Thorne, J., Tugal Tutkun, I., Turno-Krecicka, A., Van Calster, J., van der Horst-Bruinsma, I., Vidovic Valentincic, N., Vitale, A., Voorduin Ramos, S., Vukojevic, N., Wakefield, D., Willermain, F., Yalcindag, N., Yamamoto, J. H., Yeh, S., Zemaitiene, R., and Ziouzina, O.

Published
2018

43. Genetic diagnostic profiling in axial spondyloarthritis: a real-world study

Author

Thomas, G.P., Willner, D., Robinson, P.C., Cortes, A., Duan, R., Rudwaleit, M., Akkoc, N., Braun, J., Chou, C.T., Maksymowych, W.P., Ozgocmen, S., Roussou, E., Sieper, J., Valle-Onate, R., Heijde, D. van der, Wei, J., Leo, P., Brown, M.A., and Int Genetics Ankylosing Spondyli

Subjects
genetic prediction, ankylosing spondylitis, classification criteria, spondyloarthropathies
Published
2017

44. THU0218 The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry

Author

Uslu, S., primary, Can, G., additional, Senel, S., additional, Dalkilic, E., additional, Inanc, N., additional, Akar, S., additional, Kocaer, S.B., additional, Birlik, M., additional, Capar, S., additional, Akkoc, N., additional, and Onen, F., additional

Published
2018
Full Text
View/download PDF

45. AB0278 Investigation of poor prognostic factors among rheumatoid arthritis patients in turkbio registry

Author

Inanc, N., primary, Ertürk, Z., additional, Ozen, G., additional, Dalkılıç, E., additional, Koca, S.S., additional, Can, G., additional, Karatas, A., additional, Pehlivan, Y., additional, Yazici, A., additional, Cefle, A., additional, Akar, S., additional, Senel, S., additional, Oz, B., additional, Akkoc, N., additional, and Direskeneli, H., additional

Published
2018
Full Text
View/download PDF

46. AB0835 Comparison of long term anti-tnf survival in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis; data from turkbio registry

Author

Can, G., primary, Dalkilic, E., additional, Pehlivan, Y., additional, Senel, S., additional, Akar, S., additional, Solmaz, D., additional, Koca, S.S., additional, Inanc, N., additional, Atagunduz, P., additional, Yazıcı, A., additional, Cefle, A., additional, Goker, B., additional, Zengın, B., additional, Uslu, S., additional, Akkoc, N., additional, and Onen, F., additional

Published
2018
Full Text
View/download PDF

47. AB0482 Similar efficacy of tofacitinib on disease activity in rheumatoid arthritis patients with and without previous biologicals; results from the turkbio registry

Author

Zengin, B., primary, Inanç, N., additional, Akar, S., additional, Can, G., additional, Dalkilic, E., additional, Tufan, A., additional, Senel, S., additional, Serdar Koca, S., additional, Capar, S., additional, Yarkan Tugsal, H., additional, Birlik, M., additional, Akkoc, N., additional, and Onen, F., additional

Published
2018
Full Text
View/download PDF

49. FRI0134 Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?

Author

Inanc, N., primary, Ozen, G., additional, Yalcinkaya, Y., additional, Dalkilic, E., additional, Koca, S.S., additional, Can, G., additional, Karataş, A., additional, Pehlivan, Y., additional, Yazıcı, A., additional, Cefle, A., additional, Tufan, A., additional, Akar, S., additional, Senel, S., additional, Oz, B., additional, Akkoc, N., additional, and Onen, F., additional

Published
2018
Full Text
View/download PDF

50. A PROPOSAL FOR THE DEFINITION OF EARLY SYMPTOMATIC KNEE OSTEOARTHRITIS FROM AN INTERNATIONAL CONSENSUS PROMOTED BY THE ITALIAN SOCIETY FOR RHEUMATOLOGY (SIR)

Author

Carmona, L., Akkoc, N., Minisola, G., Scarpellini, M., Bagnato, G. F., Martusevich, N., Maheu, E., Frediani, B., DIRAÇOĞLU, Demirhan, Bianchi, G., Di Matteo, L., Denisov, L., Aslanidis, S., Collaku, L., Barskova, T., Babic-Naglic, D., Moreno Muelas, J. V., Herrero-Beaumont, G., Matucci-Cerinic, M., Rashkov, R., Ionescu, R., Damjanov, N., Chevalier, X., Bizzi, E., Ramonda, R., Branco, J., Migliore, A., and Scire, C. A.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results